UPB · Upstream Bio, Inc.
$4.85
-0.19 (-3.77%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared May 13, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements. The Company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these condensed consolidated financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$293.57M
Shares
54.77M
Volume · Oct 5
1.01M
Avg daily vol (3M)
598.16K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.85
Open$5.07
Day$4.67–5.10
52W close$4.85–32.60
Avg vol 30d640K
Short int4.5M · 8.2% float · 6.8d
Short vol30%
Last earningsAug 11, 2026
DataOct 2024–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 5 wks
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$3.16M
Trailing 12 months
Net income (TTM)
−$156.50M
Trailing 12 months
Revenue growth YoY
-17.5%
Year over year
Operating margin
-5,382.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$261.31M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.5%
Year over year · more shares
Price change (1Y)
-72.9%
Trailing year
Short interest
8.2%
Latest settlement · 6.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−59%
below
Price vs 50-day avg
−22%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−53%
trailing
YTD return
−82%
this year
Relative strength
−65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $12 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +36 funds added
Insider flow
Distributing
Net -$27.6K over 90 days · 100% sells
Short interest
Rising
8.20% of float · ▲ +9.7% MoM · 6.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
150 holders — near 1-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+52%
Y/Y
Free cash flow
$-133.4M
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−85%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−59%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $6 › 200d $12 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +36 funds added
Insider flow
Distributing
Net -$27.6K over 90 days · 100% sells
Short interest
Rising
8.20% of float · ▲ +9.7% MoM · 6.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
150 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $5 · 0%
Range high $33
vs 200-day avg -59%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| stock-based compensation expense (general and administrative personnel expenses) | $2.4M | the three months ended June 30, 2026 filing | — |
| stock-based compensation expense (research and development personnel expenses) | $2M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UPB
this stock
Upstream Bio, Inc.
|
$293.57M | -82.1% | +20.4% | — | 8.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UPB | -8.5% | -19.3% | -53.1% | -8.0% | -82.1% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -9.7% | -19.9% | -64.7% | -9.6% | -95.8% |